The Technical Analyst
Cocrystal Pharma Inc [COCP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cocrystal Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.76% $1.562
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 15.89 mill |
| EPS: | -1.870 |
| P/E: | -0.840 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 10.17 mill |
| Avg Daily Volume: | 0.0141 mill |
| RATING 2024-04-23 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.840 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.14x |
| Company: PE -0.840 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.55 (63.02%) $0.984 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.449 - 1.671 ( +/- 7.12%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-07-18 | Frost Phillip Md Et Al | Buy | 19 333 | Stock Options (Right to Buy) |
| 2023-07-18 | Japour Anthony J | Buy | 13 567 | Stock Options (Right to Buy) |
| 2023-07-18 | Martin James Joseph | Buy | 30 000 | Stock Options (Right to Buy) |
| 2023-07-18 | Kornberg Roger D. | Buy | 24 417 | Stock Options (Right to Buy) |
| 2023-07-18 | Lee Sam | Buy | 30 000 | Stock Options (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 92 transactions |
| Buy: 58 610 813 | Sell: 4 956 864 |
Forecast:
13:50 - $1.549
Live Trading Signals (every 1 min)
Forecast
1: 12:20 - $1.547
Forecast 2: 13:10 - $1.549
Forecast 3: 13:50 - $1.549
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $1.562 (2.76% ) |
| Volume | 0.0007 mill |
| Avg. Vol. | 0.0141 mill |
| % of Avg. Vol | 5.26 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For COCP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
COCP
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Latest Press Releases
2024-03-28 08:00:00 - Press Release
Cocrystal Pharma Reports 2023 Financial Results And Provides Updates On Its Antiviral Drug-development Programs
Bothell, wash., march 28, 2024 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (cocrystal or the company) reports financial results for the 12 months ended december 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
2024-03-19 08:00:00 - Press Release
Cocrystal Pharma Receives Pre-ind Responses From The Fda On Oral Cc-42344 For Treating Influenza A
Feedback provides greater clarity on regulatory requirements for planned phase 2b trial bothell, wash., march 19, 2024 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) announces it has received pre-investigational new drug (pre-ind) feedback from the u.s. food and drug administration (fda) regarding cc-42344 as a potential oral treatment for pandemic and seasonal influenza a.
2024-03-05 08:30:00 - Press Release
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development And 2024 Value Catalysts In New Ceo Video Interview On Planet Microcap
Los angeles, ca / accesswire / march 5, 2024 / planet microcap today published a new video interview with jim martin, co-ceo and cfo, from cocrystal pharma, inc. (nasdaq:cocp), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including sars-cov-2) noroviruses and hepatitis c viruses, according to the company's website (see here: https://www.cocrystalpharma.com/). click the following link to watch the video interview: cocrystal pharma discusses antiviral therapeutics' clinical development and 2024 value catalysts you can follow planet microcap on twitter, linkedin, youtube please review important disclosures on our website at: https://snn...
2023-12-06 08:00:00 - Press Release
Cocrystal Pharma Announces First-patient-in For Phase 2a Human Challenge Study Evaluating Oral Cc-42344 In Pandemic And Seasonal Influenza A
Bothell, wash., dec. 06, 2023 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) announces the achievement of first-patient-in for the phase 2a human challenge clinical trial with cc-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza a. this randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, viral and clinical measurements of influenza a infection in subjects dosed with oral cc-42344 treatment.
2023-11-29 08:00:00 - Press Release
Cocrystal Pharma Highlights Its Novel Inhaled And Oral Influenza A Antiviral Cc-42344 At The World Vaccine Congress West Coast
Bothell, wash., nov. 29, 2023 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”), announces the presentation of favorable data demonstrating activity of its potent broad-spectrum pb2 inhibitor cc-42344 against pandemic and seasonal influenza a strains at the world vaccine congress west coast. cocrystal has initiated a phase 2a human challenge trial with oral cc-42344 in the uk in subjects infected with influenza a, and plans to begin a phase 1 trial with inhaled cc-42344 as a potential influenza a treatment and prophylaxis in australia in the first half of 2024.
Latest News
2023-11-27 08:00:00 - GlobeNewsWire
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, Chief Financial Officer and Co-Chief Executive Officer, will present a Company overview at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference on Monday, December 4 at 1:30 p.m. Eastern time. The conference is being held December 3-5 at the College of Business Executive Education Building at Florida Atlantic University in Boca Raton, Fla.
2023-09-05 08:00:00 - GlobeNewsWire
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
BOTHELL, Wash., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel small molecule antiviral therapeutics, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Cocrystal presentation will be available on the IR Calendar section of the Company's website beginning Monday, September 11 at 7:00 a.m. Eastern time.
2023-04-10 10:28:20 - PennyStocks
Penny Stocks To Buy Now? 4 Under $3 To Watch This Week
2022-10-05 08:00:00 - GlobeNewsWire
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James Securities 2022 Small Cap Growth Conference on Wednesday, October 12, 2022 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time). The conference is being held at the Wyndham Grand Hotel in Jupiter, Fla.
2022-05-18 08:00:00 - GlobeNewsWire
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 10:00 a.m. Eastern Time. The hybrid in-person and virtual conference is being held at the Fontainebleau Miami Beach Hotel in Miami Beach.
2022-04-19 08:00:00 - GlobeNewsWire
Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference
BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company overview at the hybrid in-person and virtual Life Science Innovation Northwest 2022 (LSINW) Conference being held April 20-21, 2022 at the Washington State Convention Center in Seattle. Dr. Lee's presentation is scheduled during the Neuroscience & Pharmaceuticals segment on Wednesday, April 20 at 3:25 p.m. Pacific time.
2022-04-12 11:08:04 - Benzinga
Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial
Cocrystal Pharma Inc (NASDAQ: COCP) reported preliminary results of a Phase 1 study with CC-42344, a broad-spectrum oral antiviral to treat pandemic and seasonal influenza A. The ongoing Phase 1 trial, designed to evaluate CC-42344 administered in single-ascending and multiple-.
2022-01-27 12:22:31 - Benzinga
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19
CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication.
2021-12-08 13:20:18 - PennyStocks
4 Biotech Penny Stocks to Watch With New Catalysts
These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-11-15 13:55:13 - Zacks Investment Research
Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates
Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?